BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28108772)

  • 1. Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery.
    Yamashita K; Makino T; Tanaka K; Yamasaki M; Yamamoto M; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    World J Surg; 2017 Jun; 41(6):1566-1574. PubMed ID: 28108772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
    Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
    Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
    Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
    World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study.
    Takashi S; Satoshi Y; Akihiko O; Naoya Y; Yusuke T; Kentaro M; Yu O; Yasuaki N; Koichi Y; Takashi F; Ryo O; Isamu H; Chikara K; Kosuke N; Yasuhiro T; Kazuhiko Y; Hideaki S
    Esophagus; 2021 Jan; 18(1):65-71. PubMed ID: 32715348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma.
    Kochi R; Yajima S; Nanami T; Suzuki T; Oshima Y; Tokura N; Takatsuka J; Funahashi K; Tochigi N; Shimada H
    Clin J Gastroenterol; 2018 Aug; 11(4):278-281. PubMed ID: 29497977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of perioperative change in serum p53 antibody titers in esophageal squamous cell carcinoma.
    Haneda R; Mayanagi S; Inoue M; Ishii K; Morita Y; Kikuchi H; Hiramatsu Y; Takeuchi H; Tsubosa Y
    Esophagus; 2023 Oct; 20(4):669-678. PubMed ID: 37212971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
    Chung Y; Law S; Kwong DL; Luk JM
    Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma.
    Shimada H; Nabeya Y; Okazumi S; Matsubara H; Funami Y; Shiratori T; Hayashi H; Takeda A; Ochiai T
    Surgery; 2002 Jul; 132(1):41-7. PubMed ID: 12110794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular factors and criteria for predicting the response to neoadjuvant treatment in patients with esophageal squamous cell carcinoma (ESCC) -- responder/non-responder.
    Predescu D; Gheorghe M; Boeriu M; Constantin A; Iosif C; Anghel R; Constantinoiu S
    Chirurgia (Bucur); 2012; 107(5):583-90. PubMed ID: 23116831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
    Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma.
    Takahashi K; Miyashita M; Nomura T; Makino H; Futami R; Kashiwabara M; Katsuta M; Tajiri T
    Dis Esophagus; 2007; 20(2):117-22. PubMed ID: 17439594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy.
    Chen YF; Li Q; Chen DT; Pan JH; Chen YH; Wen ZS; Zeng WA
    Cancer Biomark; 2016 Jun; 17(1):89-96. PubMed ID: 27314297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
    Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
    Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma--preliminary report.
    Nasierowska-Guttmejer A; Szawłowski A; Jastrzebska M; Jeziorski K; Radziszewski J
    Dis Esophagus; 1999; 12(2):128-31. PubMed ID: 10466045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
    Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
    World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.